Comparing the change in plasma BDNF levels from baseline to 6 months later, fewer cancer patients experienced a reduction of plasma BDNF levels as the number of Met alleles increased (Val/Val: 67%; Val/Met: 62%; Met/Met: 50%). The gene discussed is BDNF; the disease is cancer.